Five years' experience with thymoglobulin induction in a pediatric renal transplant population

被引:22
作者
Hastings, M. Colleen
Wyatt, Robert J.
Lau, Keith K.
Jones, Deborah P.
Powell, Sandra L.
Hays, Dena W.
Gaber, Lillian W.
Gaber, A. Osama
Ault, Bettina H.
机构
[1] Univ Tennessee, Hlth Sci Ctr, Childrens Fdn Res Ctr, Dept Pediat, Memphis, TN 38103 USA
[2] Lebonheur Childrens Hosp & Med Ctr, Memphis, TN USA
[3] Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA
[4] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA
关键词
thymoglobulin; renal transplant; pediatrics;
D O I
10.1111/j.1399-3046.2006.00509.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Antibody induction therapy is used in the majority of pediatric patients undergoing renal transplantation. Our center has previously reported short-term outcomes with TMG as induction therapy. We now present our experience over the last five yr. Patients received TMG intra- and post-operatively at a dose of 1.5 mg/kg/day. The dose was decreased to 0.75 mg/kg/day or held dependent on the patient's WBC and platelet counts. Post-transplant immunosuppression also included corticosteroids, MMF, and either TAC or CSA. Patient and graft survival, number of acute rejection episodes, creatinine clearance, incidence and type of infections, and trough levels of calcineurin inhibitor drugs were monitored during the follow-up period. Thirty-four renal transplants were performed in 33 pediatric patients ranging in age from 1.7 to 17.8 yr. Seventeen rejection episodes occurred during the time of follow-up with three patients having more than one episode, but only three episodes occurred within the first year after transplantation. Three patients had graft loss in the first week after transplantation from primary non-function (1) or technical failure/thrombosis (2). Graft losses occurred in seven additional patients during the time of follow-up with the first loss occurring at 17.7 months. Among patients with functional grafts at one wk after transplant, graft survival at one and three yr was 100% and 73% respectively. There were no patient deaths. There were no cases of post-transplant lymphoproliferative disease or other malignancy. One patient had symptomatic CMV disease. TMG is safe and effective as induction therapy in pediatric renal transplant patients. Late graft loss remains a challenge in the pediatric patient population, particularly in adolescents.
引用
收藏
页码:805 / 810
页数:6
相关论文
共 21 条
[1]   Short course induction immunosuppression with thymoglobulin for renal transplant recipients [J].
Agha, IA ;
Rueda, J ;
Alvarez, A ;
Singer, GG ;
Miller, BW ;
Flavin, K ;
Lowell, JA ;
Shenoy, S ;
Howard, TK ;
Ramachandran, V ;
Irish, W ;
Schnitzle, MA ;
Brennan, DC .
TRANSPLANTATION, 2002, 73 (03) :473-475
[2]   Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis [J].
Akalin, E ;
Sehgal, V ;
Ames, S ;
Hossain, S ;
Daly, L ;
Barbara, M ;
Bromberg, JS .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :731-735
[3]   PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL-ANTIBODY USED IN CADAVERIC RENAL-TRANSPLANTATION [J].
AMLOT, PL ;
RAWLINGS, E ;
FERNANDO, ON ;
GRIFFIN, PJ ;
HEINRICH, G ;
SCHREIER, MH ;
CASTAIGNE, JP ;
MOORE, R ;
SWENY, P .
TRANSPLANTATION, 1995, 60 (07) :748-756
[4]   Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients [J].
Ault, BH ;
Honaker, MR ;
Gaber, AO ;
Jones, DP ;
Duhart, BT ;
Powell, SL ;
Hays, DW ;
Wyatt, RJ .
PEDIATRIC NEPHROLOGY, 2002, 17 (10) :815-818
[5]   A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [J].
Brennan, DC ;
Flavin, K ;
Lowell, JA ;
Howard, TK ;
Shenoy, S ;
Burgess, S ;
Dolan, S ;
Kano, JM ;
Mahon, M ;
Schnitzler, MA ;
Woodward, R ;
Irish, W ;
Singer, GG .
TRANSPLANTATION, 1999, 67 (07) :1011-1018
[6]   Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation [J].
Gaber, AO ;
First, MR ;
Tesi, RJ ;
Gaston, RS ;
Mendez, R ;
Mulloy, LL ;
Light, JA ;
Gaber, LW ;
Squiers, E ;
Taylor, RJ ;
Neylan, JF ;
Steiner, RW ;
Knechtle, S ;
Norman, DJ ;
Shihab, F ;
Basadonna, G ;
Brennan, DC ;
Hodge, EE ;
Kahan, BD ;
Kahana, L ;
Steinberg, S ;
Woodle, ES ;
Chan, L ;
Ham, JM ;
Stratta, RJ ;
Wahlstrom, E ;
Lamborn, KR ;
Horn, HR ;
Moran, HB ;
Pouletty, P ;
Schroeder, TJ .
TRANSPLANTATION, 1998, 66 (01) :29-37
[7]   Five-year follow up of Thymoglobulin versus ATGAM induction in adult renal transplantation [J].
Hardinger, KL ;
Schnitzler, MA ;
Miller, B ;
Lowell, JA ;
Shenoy, S ;
Koch, MJ ;
Enkvetchakul, D ;
Ceriotti, C ;
Brennan, BC .
TRANSPLANTATION, 2004, 78 (01) :136-141
[8]   Renal allograft outcomes in African American versus Caucasian transplant recipients in the tacrolimus era [J].
Hardinger, KL ;
Stratta, RJ ;
Egidi, MF ;
Alloway, RR ;
Shokouh-Amiri, MH ;
Gaber, LW ;
Grewal, HP ;
Honaker, MR ;
Vera, S ;
Gaber, AO .
SURGERY, 2001, 130 (04) :738-745
[9]   Rabbit antithymocyte globulin as induction immunotherapy for pediatric deceased donor kidney transplantation [J].
Kamel, MH ;
Mohan, P ;
Little, DM ;
Awan, A ;
Hickey, DP .
JOURNAL OF UROLOGY, 2005, 174 (02) :703-707
[10]   Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: A single-center report [J].
Khositseth, S ;
Matas, A ;
Cook, ME ;
Gillingham, KJ ;
Chavers, BM .
TRANSPLANTATION, 2005, 79 (08) :958-963